The BioTech behind a drug to combat COVID-19 has raised a pre-IPO funding round of £3.5 million. Glasgow-based ILC Therapeutics, which in May strengthened its board and management, has added another three names to the board to advance its lead novel hybrid interferon drug candidate Alfacyte.  The startup is a pioneer in the discovery and development of a new class … Continue reading BioTech behind COVID drug raises pre-IPO £3.5m round